Adaptimmune Therapeutics Debt 2024

Adaptimmune Therapeutics Aktienanalyse

What does Adaptimmune Therapeutics do?

Adaptimmune Therapeutics PLC is a biotechnology company specializing in the development of immunotherapies against cancer. The company was founded in 2008 and is headquartered in Oxfordshire, England. Adaptimmune focuses on harnessing the human immune system to target and destroy cancer cells. The company's business model primarily revolves around the research and development of therapeutic products for different types of cancer. It develops and utilizes T-cell receptor (TCR) therapies to specifically target cancer cells. TCRs are proteins on T-cells that can recognize and kill cancer cells. Adaptimmune harnesses this property of TCRs to develop specific receptors targeted against certain types of cancer. Adaptimmune has three different business segments: oncology, autoimmune diseases, and infections. However, the focus is primarily on oncology. In this area, Adaptimmune concentrates on developing TCR products for various types of cancer such as pancreatic cancer, esophageal cancer, and lung cancer. One of Adaptimmune's key products is the T-cell therapy known as SPEAR (Specific Peptide Enhanced Affinity Receptor), which is individually developed for each patient. This therapy utilizes TCRs targeting specific tumor cells. The TCRs are optimized so that the body's own T-cells can precisely recognize and destroy the cancer cells. SPEAR has already shown promising results in a clinical study for melanoma patients. Another important product of Adaptimmune is ADP-A2M4. This immunotherapy also utilizes TCRs developed to target specific cancer cells. ADP-A2M4 is currently in Phase II clinical trials for advanced or metastatic esophageal cancer or gastric cancer. Adaptimmune also has partnerships with other companies and organizations such as GSK, NY-ESO-1, Universal Cells, and the MD Anderson Cancer Center. This collaboration expands the company's portfolio and enables the development of innovative immunotherapies. Overall, Adaptimmune's goal is to develop innovative TCR products for the treatment of various types of cancer. With its focus on immunotherapies, the company has created unique solutions to mobilize the human immune system specifically against cancer. Adaptimmune has the potential to revolutionize cancer treatment and improve the lives of millions of people. Adaptimmune Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Adaptimmune Therapeutics's Debt Structure

Adaptimmune Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Adaptimmune Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Adaptimmune Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Adaptimmune Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Adaptimmune Therapeutics stock

What is the debt of Adaptimmune Therapeutics this year?

Adaptimmune Therapeutics has a debt level of -143.99 USD this year.

What was the debt of Adaptimmune Therapeutics compared to the previous year?

The debt of Adaptimmune Therapeutics has increased by 33.33% compared to the previous year increased.

What are the consequences of high debt for investors in Adaptimmune Therapeutics?

High debt can pose a risk for investors of Adaptimmune Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Adaptimmune Therapeutics?

Low debt means that Adaptimmune Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Adaptimmune Therapeutics affect the company?

An increase in debt of Adaptimmune Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Adaptimmune Therapeutics affect the company?

A reduction in debt of Adaptimmune Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Adaptimmune Therapeutics?

Some factors that can influence the debt of Adaptimmune Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Adaptimmune Therapeutics so important for investors?

The debts of Adaptimmune Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Adaptimmune Therapeutics take to change the debt?

To change the debt, Adaptimmune Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Adaptimmune Therapeutics pay?

Over the past 12 months, Adaptimmune Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptimmune Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptimmune Therapeutics?

The current dividend yield of Adaptimmune Therapeutics is .

When does Adaptimmune Therapeutics pay dividends?

Adaptimmune Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptimmune Therapeutics?

Adaptimmune Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Adaptimmune Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptimmune Therapeutics located?

Adaptimmune Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptimmune Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptimmune Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Adaptimmune Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Adaptimmune Therapeutics in the year 2023?

In the year 2023, Adaptimmune Therapeutics distributed 0 USD as dividends.

In which currency does Adaptimmune Therapeutics pay out the dividend?

The dividends of Adaptimmune Therapeutics are distributed in USD.